A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions

Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%. In Northeast China's cold regions, metabolic diseases such as hypertension, hyperlipidemia, and diabetes are prevalent and may influence HCC prognosis. Recently, PD-1/PD-L1 inhibitor-based combination regimens (with targeted therapy, chemotherapy, or locoregional treatment) have achieved major breakthroughs, significantly extending overall and progression-free survival. These regimens have become the first-line backbone for unresectable HCC. Investigating their real-world effectiveness and safety is critical for optimizing regional treatment strategies.

NCT Number	NCT07645209
Lead Sponsor	Harbin Medical University Collaborators: Liaoning Cancer Hospital & Institute, China-Japan Union Hospital, Jilin University, First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University
Conditions	Liver Cancer
Enrollment	1,000 participants
Start Date	2026-05-13
Primary Completion	2028-05-13 (estimated)
Study Completion	2029-05-13 (estimated)
Updated on ClinicalTrials.gov	2026-06-12